Search

With new vaccines come new challenges – and the need for new tools. Can mass spectrometry solve the problem of impurities?

As we transition into the endemic phase of the pandemic, companies will have to consider how their mRNA products will be housed and stored.

Summarizing the updated lessons learned by the European Medicines Agency following the COVID-19 pandemic.

How the European Commission has struck deals to secure manufacturing capacity for future emergencies.

The latest issue of The Bioprocess Curator included a lot of interesting news about vaccines. In case you missed it, here's some of the top stories.

The development of a CMV vaccine has been 50 years in the making.

Experts from Sartorius give advice on the next generation processes and facilities for mRNA manufacture.

In our second C+G Champions installment, we ask industry leaders in the cell and gene field to answer key questions about the industry.

How can our knowledge of mRNA vaccine development influence our Industry 4.0 journeys?

So much has already been achieved with RNA – and it’s only going to get better.